Literature DB >> 27533984

New oral anticoagulants: a practical guide for physicians.

Rocio Hinojar1, Jose Julio Jiménez-Natcher2, Covadonga Fernández-Golfín2, Jose Luis Zamorano2.   

Abstract

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Unlike VKAs, these anticoagulants do not require routine INR monitoring and possess favorable pharmacological properties. The lack of an effective antidote, their cost, or reservations in patients with kidney disease may explain their slow rate of expansion. Safe and effective use of these new drugs will depend on clinical experience amongst the medical community. This review discusses the current NOACs, providing practical and easy-to-use algorithms for application in the clinical routine. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; New oral anticoagulants; Stroke

Mesh：

Substances：

Year:  2015        PMID： 27533984     DOI： 10.1093/ehjcvp/pvv002

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  9 in total

1.  Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.

Authors:  Rochelle Sweis; José Biller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

Review 2.  Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.

Authors:  Sujan T Reddy; T C Cossey; Sean I Savitz; James C Grotta
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 3.  New Oral Anticoagulants and Their Reversal Agents.

Authors:  Andrea Morotti; Joshua N Goldstein
Journal:  Curr Treat Options Neurol       Date:  2016-11       Impact factor: 3.598

4.  Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry.

Authors:  Judit Papp; Endre Zima; Ramon Bover; Rasa Karaliute; Andrea Rossi; Catherine Szymanski; Rossella Troccoli; Jonas Schneider; Morten Wang Fagerland; A John Camm; Dan Atar
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2017-07-01

5.  Value of pharmacy services upon admission to an orthopedic surgery unit.

Authors:  Ahmad El Ouweini; Lamis R Karaoui; Nibal Chamoun; Chahine Assi; Kaissar Yammine; Elsy Ramia
Journal:  J Pharm Policy Pract       Date:  2021-12-06

6.  Effects of Apixaban, Rivaroxaban, Dabigatran and Enoxaparin on Histopathology and Laboratory Parameters in Achilles Tendon Injury: An in vivo Study.

Authors:  Sema Avci; Huseyin Gungor; Alper Serhat Kumru; Mahmut Sahin; Arzu Gezer; Uzeyir Gok; Haki Kara; Mucahit Avcil
Journal:  Saudi J Med Med Sci       Date:  2021-06-23

7.  Economy- and Social-Based Strategies for Anticoagulation of Patients with Atrial Fibrillation.

Authors:  Andressa Zulmira Avila Guerrero; Enia Lucia Coutinho; Marcos Bosi Ferraz; Claudio Cirenza; Marcelo Cincotto Esteves Dos Santos; José Roberto Ferraro; Angelo Amato Vincenzo de Paola
Journal:  Arq Bras Cardiol       Date:  2022-01       Impact factor: 2.000

8.  Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol.

Authors:  Harsukh Benipal; Anne Holbrook; J Michael Paterson; James Douketis; Gary Foster; Lehana Thabane
Journal:  BMJ Open       Date:  2020-09-22       Impact factor: 2.692

9.  Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation.

Authors:  Bruria Hirsh Raccah; Yevgeni Erlichman; Arthur Pollak; Ilan Matok; Mordechai Muszkat
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-06-01       Impact factor: 2.457
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.